KRAS G12C: The Complete 2025 Clinical Trial Guide

KRAS G12C is one of the most common oncogenic driver mutations, found in approximately 13% of non-small cell lung cancers and 3% of colorectal cancers.

What is KRAS G12C?

KRAS is a gene that helps control cell growth. The G12C mutation causes the KRAS protein to become permanently "on," leading to uncontrolled cell division. For decades, KRAS was considered "undruggable"—until now.

FDA-Approved Treatments

Sotorasib (Lumakras) and adagrasib (Krazati) are now approved for KRAS G12C lung cancer patients who have previously received treatment.

Current Clinical Trials

Multiple trials are exploring KRAS G12C inhibitors in combination with immunotherapy, as first-line treatment, and in other cancer types.

Finding the Right Trial

Use ClinicalMatch to search for KRAS G12C-specific trials near you. Filter by phase, distance, and combination therapies to find the best match.